ERCC2 and neoplasm: For patients with EGFR wild type tumours, treatment duration was generally shorter, with median TTD1 (95% CI), TTD2, and TTD3 of 4.0 months (3.3, 4.6), 2.8 months (1.9, 4.8), and 2.1 months (1.3, 5.8), respectively (Table 3, Figure 2).